Itacitinib in Treating Patients With Refractory Metastatic/Advanced Soft Soft Tissue Sarcomas

Complete Title: A Pilot Study Examining the Impact of the Jak1 Inhibitor Itacitinib On the Sarcoma Tumor Immune Microenvironment

Trial Phase: I

Investigator: Michael Wagner, MD

This pilot phase II trial studies how well itacitinib works in treating patients with soft tissue sarcomas that do not respond to treatment (refractory) and have spread to other parts of the body (advanced/metastatic). Itacitinib may cause changes in the immune system and the body's immune response to cancer, which may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Keywords:

Sarcoma, Synovial
Liposarcoma, Myxoid/Round Cell
Sarcoma, Metastatic
Leiomyosarcoma
Neoplasms, Soft Tissue

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Join a Clinical Trial

Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.

Contact Us

If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.